PDF(Pubmed)
Abstract：
BACKGROUND: Oxaliplatin-induced peripheral neuropathy (OIPN) is a common and dose-limiting toxicity that markedly limits the use of oxaliplatin and affects quality of life. Statins have been shown to exert neuroprotective effects in preclinical settings. The aim of the present study was to clarify whether statins prevented OIPN in patients with colorectal cancer (CRC) receiving adjuvant CAPOX therapy.
METHODS: We examined 224 patients who received adjuvant CAPOX therapy for CRC between July 2010 and December 2021 at our hospital. Patients were divided into \"Statin\" and \"Non-statin\" groups based on statin use. Details on and the adverse events of adjuvant CAPOX therapy were examined in association with statin use.
RESULTS: Thirty-one patients (14%) were treated with statins. There were no intergroup differences in the relative dose intensity or number of CAPOX cycles between the Statin and Non-statin groups. In total, 94% of patients in the Statin group and 95% of those in the Non-statin group developed OIPN (p=0.67). The severity of OIPN was similar between the two groups (p=0.89). The frequency of treatment delays in CAPOX did not significantly differ between the Statin and Non-statin groups (16% vs. 11%, p=0.45).
CONCLUSIONS: The efficacy of statins to attenuate OIPN during adjuvant CAPOX therapy was not apparent in the current study. Further studies are needed to confirm the present results.
METHODS: We examined 224 patients who received adjuvant CAPOX therapy for CRC between July 2010 and December 2021 at our hospital. Patients were divided into \"Statin\" and \"Non-statin\" groups based on statin use. Details on and the adverse events of adjuvant CAPOX therapy were examined in association with statin use.
RESULTS: Thirty-one patients (14%) were treated with statins. There were no intergroup differences in the relative dose intensity or number of CAPOX cycles between the Statin and Non-statin groups. In total, 94% of patients in the Statin group and 95% of those in the Non-statin group developed OIPN (p=0.67). The severity of OIPN was similar between the two groups (p=0.89). The frequency of treatment delays in CAPOX did not significantly differ between the Statin and Non-statin groups (16% vs. 11%, p=0.45).
CONCLUSIONS: The efficacy of statins to attenuate OIPN during adjuvant CAPOX therapy was not apparent in the current study. Further studies are needed to confirm the present results.
摘要：
背景：奥沙利铂诱导的周围神经病变（OIPN）是一种常见的剂量限制性毒性，明显限制了奥沙利铂的使用并影响生活质量。他汀类药物已被证明在临床前环境中发挥神经保护作用。本研究的目的是阐明他汀类药物是否可以预防接受CAPOX辅助治疗的结直肠癌（CRC）患者的OIPN。
方法：我们检查了在2010年7月至2021年12月期间在我院接受CAPOX辅助治疗CRC的224例患者。根据他汀类药物的使用将患者分为“他汀类药物”和“非他汀类药物”组。研究了CAPOX辅助治疗的细节和不良事件与他汀类药物使用的相关性。
结果：31例患者（14%）接受他汀类药物治疗。他汀组和非他汀组之间的相对剂量强度或CAPOX周期数没有组间差异。总的来说,他汀类药物组中94%的患者和非他汀类药物组中95%的患者发生OIPN(p=0.67)。两组之间OIPN的严重程度相似（p=0.89）。他汀组和非他汀组之间CAPOX的治疗延迟频率没有显着差异（16％vs.11%,p=0.45)。
结论：在目前的研究中，他汀类药物在辅助CAPOX治疗期间减弱OIPN的功效并不明显。需要进一步的研究来证实目前的结果。
方法：我们检查了在2010年7月至2021年12月期间在我院接受CAPOX辅助治疗CRC的224例患者。根据他汀类药物的使用将患者分为“他汀类药物”和“非他汀类药物”组。研究了CAPOX辅助治疗的细节和不良事件与他汀类药物使用的相关性。
结果：31例患者（14%）接受他汀类药物治疗。他汀组和非他汀组之间的相对剂量强度或CAPOX周期数没有组间差异。总的来说,他汀类药物组中94%的患者和非他汀类药物组中95%的患者发生OIPN(p=0.67)。两组之间OIPN的严重程度相似（p=0.89）。他汀组和非他汀组之间CAPOX的治疗延迟频率没有显着差异（16％vs.11%,p=0.45)。
结论：在目前的研究中，他汀类药物在辅助CAPOX治疗期间减弱OIPN的功效并不明显。需要进一步的研究来证实目前的结果。
